Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of GDC-0810 on Pravastatin PK in Healthy Females
NCT02621957Phase 1Completed
- Sponsor
- Genentech
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brilanestrant in breast cancer, sponsored by Genentech. Primary endpoints: Maximum Observed Concentration of Pravastatin, Time to Maximum Concentration of Pravastatin and 7 more. Started Dec 2015; status: completed.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02621957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621957.